Amphastar Pharmaceuticals, Inc. (AMPH) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
60/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseAMPH / S&P 3.01% / 15.20% |
LoseAMPH / S&P 1.02% / 15.00% |
LoseAMPH / S&P -36.70% / 50.40% |
| 2026-Q10/3 |
LoseAMPH / S&P -26.85% / -4.33% |
LoseAMPH / S&P -1.39% / 11.30% |
LoseAMPH / S&P -39.86% / 27.70% |
| 2025-Q40/3 |
LoseAMPH / S&P 0.49% / 2.65% |
LoseAMPH / S&P -1.65% / 9.00% |
LoseAMPH / S&P -33.66% / 13.40% |
| 2025-Q31/3 |
WinAMPH / S&P 16.07% / 8.12% |
LoseAMPH / S&P -0.03% / 4.61% |
LoseAMPH / S&P -24.92% / 13.45% |
| 2025-Q20/3 |
LoseAMPH / S&P -20.80% / 10.94% |
LoseAMPH / S&P 1.37% / 4.83% |
LoseAMPH / S&P -14.97% / 10.63% |
| 2025-Q11/3 |
LoseAMPH / S&P -21.92% / -4.27% |
WinAMPH / S&P 8.05% / 4.98% |
LoseAMPH / S&P -4.83% / 10.57% |
| 2024-Q42/3 |
LoseAMPH / S&P -23.49% / 2.41% |
WinAMPH / S&P 13.59% / 5.25% |
WinAMPH / S&P 18.15% / 6.15% |
| 2024-Q33/3 |
WinAMPH / S&P 21.32% / 5.89% |
WinAMPH / S&P 20.33% / 5.89% |
WinAMPH / S&P 18.04% / 6.11% |
| 2024-Q22/3 |
LoseAMPH / S&P -8.90% / 4.28% |
WinAMPH / S&P 31.80% / 5.38% |
WinAMPH / S&P 61.86% / 5.12% |
| 2024-Q12/3 |
LoseAMPH / S&P -29.01% / 10.56% |
WinAMPH / S&P 30.38% / 5.71% |
WinAMPH / S&P 62.92% / 5.59% |
| 2023-Q43/3 |
WinAMPH / S&P 34.49% / 11.69% |
WinAMPH / S&P 29.14% / 6.81% |
WinAMPH / S&P 48.00% / 7.78% |
| 2023-Q32/3 |
LoseAMPH / S&P -19.98% / -3.27% |
WinAMPH / S&P 24.02% / 7.52% |
WinAMPH / S&P 70.00% / -5.03% |
| 2023-Q23/3 |
WinAMPH / S&P 53.25% / 8.74% |
WinAMPH / S&P 13.41% / 9.50% |
WinAMPH / S&P 8.38% / -8.57% |
| 2023-Q13/3 |
WinAMPH / S&P 33.83% / 7.50% |
WinAMPH / S&P 13.96% / 10.77% |
WinAMPH / S&P 9.88% / -15.69% |
| 2022-Q42/3 |
LoseAMPH / S&P -0.28% / 7.56% |
WinAMPH / S&P 13.98% / 11.88% |
WinAMPH / S&P 40.00% / -17.99% |
| 2022-Q32/3 |
LoseAMPH / S&P -19.23% / -4.88% |
WinAMPH / S&P 17.45% / 13.47% |
WinAMPH / S&P 108.33% / -1.41% |
| 2022-Q23/3 |
WinAMPH / S&P -3.09% / -16.10% |
WinAMPH / S&P 24.19% / 13.71% |
WinAMPH / S&P 752.38% / 11.04% |
| 2022-Q13/3 |
WinAMPH / S&P 54.14% / -4.60% |
WinAMPH / S&P 23.61% / 15.97% |
WinAMPH / S&P 3140.00% / 42.23% |
| 2021-Q43/3 |
WinAMPH / S&P 22.51% / 11.03% |
WinAMPH / S&P 25.13% / 15.00% |
WinAMPH / S&P 4066.67% / 96.40% |
| 2021-Q32/3 |
LoseAMPH / S&P -5.70% / 0.58% |
WinAMPH / S&P 22.38% / 10.77% |
WinAMPH / S&P 414.29% / 69.42% |
| 2021-Q23/3 |
WinAMPH / S&P 10.04% / 8.55% |
WinAMPH / S&P 14.98% / 6.58% |
WinAMPH / S&P 133.33% / 51.81% |
| 2021-Q11/3 |
LoseAMPH / S&P -8.90% / 6.17% |
WinAMPH / S&P 12.50% / -1.06% |
LoseAMPH / S&P -95.24% / 7.39% |
| 2020-Q41/3 |
LoseAMPH / S&P 7.25% / 12.15% |
WinAMPH / S&P 8.53% / -3.72% |
LoseAMPH / S&P -96.97% / -33.42% |
| 2020-Q31/3 |
LoseAMPH / S&P -16.52% / 8.93% |
WinAMPH / S&P 2.63% / -2.04% |
LoseAMPH / S&P -86.67% / -27.10% |
| 2020-Q22/3 |
WinAMPH / S&P 51.35% / 20.54% |
WinAMPH / S&P 3.07% / -0.46% |
LoseAMPH / S&P -91.59% / -27.11% |
| 2020-Q12/3 |
LoseAMPH / S&P -23.07% / -19.60% |
WinAMPH / S&P 3.54% / 3.47% |
WinAMPH / S&P 2000.00% / -14.75% |
| 2019-Q41/3 |
LoseAMPH / S&P -2.72% / 9.07% |
WinAMPH / S&P 9.40% / 5.36% |
LoseAMPH / S&P -925.00% / 2.99% |
| 2019-Q31/3 |
LoseAMPH / S&P -6.06% / 1.70% |
WinAMPH / S&P 23.85% / 5.02% |
LoseAMPH / S&P -850.00% / 0.21% |
| 2019-Q21/3 |
LoseAMPH / S&P 3.33% / 4.30% |
WinAMPH / S&P 30.80% / 6.64% |
LoseAMPH / S&P -663.16% / 8.65% |
| 2019-Q11/3 |
LoseAMPH / S&P 2.66% / 13.65% |
WinAMPH / S&P 30.66% / 8.12% |
LoseAMPH / S&P -155.56% / 14.29% |
| 2018-Q42/3 |
WinAMPH / S&P 3.43% / -13.52% |
WinAMPH / S&P 22.69% / 9.05% |
LoseAMPH / S&P -250.00% / 18.23% |
| 2018-Q32/3 |
WinAMPH / S&P 26.08% / 7.71% |
LoseAMPH / S&P 9.07% / 10.21% |
WinAMPH / S&P 600.00% / 19.06% |
| 2018-Q20/3 |
LoseAMPH / S&P -18.61% / 3.43% |
LoseAMPH / S&P -0.75% / 9.03% |
LoseAMPH / S&P -416.67% / 14.46% |
| 2018-Q10/3 |
LoseAMPH / S&P -2.55% / -0.76% |
LoseAMPH / S&P -4.19% / 7.68% |
LoseAMPH / S&P -152.94% / 12.46% |
| 2017-Q41/3 |
WinAMPH / S&P 7.67% / 6.64% |
LoseAMPH / S&P -5.87% / 7.03% |
LoseAMPH / S&P -60.00% / 13.82% |
| 2017-Q30/3 |
LoseAMPH / S&P 0.06% / 4.48% |
LoseAMPH / S&P -9.39% / 5.68% |
LoseAMPH / S&P -104.44% / 17.57% |
| 2017-Q21/3 |
WinAMPH / S&P 23.17% / 3.09% |
LoseAMPH / S&P -6.92% / 4.83% |
LoseAMPH / S&P -80.00% / 17.74% |
| 2017-Q11/3 |
LoseAMPH / S&P -21.28% / 6.07% |
LoseAMPH / S&P -0.60% / 3.67% |
WinAMPH / S&P 1224979098644774912.00% / 13.32% |
| 2016-Q40/3 |
LoseAMPH / S&P -2.90% / 3.82% |
LoseAMPH / S&P 1.45% / 2.09% |
LoseAMPH / S&P -433.33% / 7.05% |
| 2016-Q32/3 |
WinAMPH / S&P 17.68% / 3.85% |
WinAMPH / S&P 16.51% / 0.20% |
LoseAMPH / S&P -260.71% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AMPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -28.54% | 20.78% |
| Annualized return | -28.54% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AMPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 10.84% | 83.14% |
| Annualized return | 2.08% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | AMPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 15.22% | 319.30% |
| Annualized return | 1.43% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |